The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis
Open accessAbstract
Background and Aims Studies are needed to determine the long-term effects of bariatric surgery for patients with nonalcoholic steatohepatitis (NASH). We evaluated sequential liver samples, collected the time of bariatric surgery and 1 and 5 years later, to assess the long-term effects of bariatric surgery in patients with NASH. Methods We performed a prospective study of 180 severely obese patients with biopsy-proven NASH, defined by the NASH clinical research network histologic scores. The patients underwent bariatric surgery at a single center in France and were followed for 5 years. We obtained liver samples from 125 of 169 patients (76%) having reached 1 year and 64 of 94 patients (68%) having reached 5 years after surgery. The primary endpoint was the resolution of NASH without worsening of fibrosis at 5 years. Secondary end points were improvement in fibrosis (reduction of ≥1 stage) at 5 years and regression of fibrosis and NASH at 1 and 5 years. Results At 5 years after bariatric surgery, NASH was resolved, without worsening fibrosis, in samples from 84% of patients (n = 64; 95% confidence interval, 73.1%-92.2%). Fibrosis decreased, compared with baseline, in samples from 70.2% of patients (95% CI, 56.6%-81.6%). Fibrosis disappeared from samples from 56% of all patients (95% CI, 42.4%-69.3%) and from samples from 45.5% of patients with baseline bridging fibrosis. Persistence of NASH was associated with no decrease in fibrosis and less weight loss (reduction in body mass index of 6.3 ± 4.1 kg/m 2 in patients with persistent NASH vs reduction of 13.4 ± 7.4 kg/m 2 ; P = .017 with resolution of NASH). Resolution of NASH was observed at 1 year after bariatric surgery in biopsies from 84% of patients, with no significant recurrence between 1 and 5 years ( P = .17). Fibrosis began to decrease by 1 year after surgery and continued to decrease until 5 years ( P < .001). Conclusions In a long-term follow-up of patients with NASH who underwent bariatric surgery, we observed resolution of NASH in liver samples from 84% of patients 5 years later. The reduction of fibrosis is progressive, beginning during the first year and continuing through 5 years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In an observational study, MASH was resolved in 84% of 180 individuals with class 2 obesity and MASH 5 years after Roux-en-Y gastric bypass (66%), sleeve gastrectomy (12%) or gastric banding (22%).”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [443]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Pioglitazone therapy, GLP-1 RA therapy, and metabolic surgery have all been shown to reduce NASH activity; pioglitazone therapy and metabolic surgery may also improve hepatic fi brosis (188,292 -298).”
The cited source says what the claim attributes to it.
In the citing paper
“Wound healing in the liver is dynamic and reversible,105 with ample evidence of fibrosis regression after effective treatment of viral hepatitis, and even following bariatric surgery in patients with NASH.106”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [106]
The cited source says what the claim attributes to it.
In the citing paper
“One of the most promising developments in the field is the growing consensus that liver fibrosis can be a reversible process under certain conditions, particularly if the underlying cause of injury is removed (84–86).”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [85]
The cited source says what the claim attributes to it.
In the citing paper
“Procedures like Roux-en-Y gastric bypass (RYGB) and vertical sleeve gastrectomy (VSG) are associated with significant metabolic improvements and reductions in NAFLD severity [13,14,15], including reductions in liver fat, liver enzymes, and fibrosis [16,17,18].”
From Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review (2025) · cites this paper as [16]
In the citing paper
“The reduction of fibrosis is progressive, beginning during the first year and continuing through 5 years [4,127].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [127]
In the citing paper
“In a long-term follow-up study of patients with MASH who underwent bariatric surgery, the resolution of MASH in liver samples was observed from 84% of patients 5 years later.”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [127]
In the citing paper
“Weight loss either through lifestyle intervention68 or bariatric surgery (Roux-en-Y gastric bypass or sleeve gastrectomy)69,70 improves the lipid profile by reducing total TAGs, and increasing PC, PE and HDL concentrations.125”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [70]
In the citing paper
“Nevertheless, these interventions suggest that, like HCV and HBV, MASH fibrosis is reversible in non-cirrhotic liver, but unlike in HCV and HBV there is no evidence yet that cirrhosis in MASH is reversible (259).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [259]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Bariatric Surgery: A Systematic Review and Meta-analysis
Buchwald, H., Avidor, Y., Braunwald, E., Jensen, M. D., Pories, W., Fahrbach, K., & Schoelles, K. (2004) · JAMA · doi:10.1001/jama.292.14.1724 · Cited by 6,800
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
Sjöström, L., Narbro, K., Sjöström, C. D., Karason, K., Larsson, B., Wedel, H., Lystig, T., Sullivan, M., Bouchard, C., Carlsson, B., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066254 · Cited by 4,668
Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907
Chalasani, N., Younossi, Z. M., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K. J., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,859
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes
Schauer, P. R., Bhatt, D. L., Kirwan, J. P., Wolski, K., Aminian, A., Brethauer, S. A., Navaneethan, S. D., Singh, R. P., Pothier, C. E., Nissen, S. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1600869 · Cited by 2,934
Long-term mortality after gastric bypass surgery
Adams, T. D., Gress, R. E., Smith, S. C., Halverson, R. C., Simper, S. C., Rosamond, W. D., LaMonte, M. J., Stroup, A. M., & Hunt, S. C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066603 · Cited by 2,572
Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492
Cited by
Sorted by citations
Items 601–620 of 620
Chekuri, R., Gagal, S., Singla, V., Khan, W. F., Aggarwal, S., Shalimar, Singh, A., & Yadav, R. (2026) · Journal of Minimal Access Surgery · doi:10.4103/jmas.jmas_242_26
Gut Microbiota in NAFLD/MASLD: Functional Dysbiosis and the Gut–Liver Axis in Disease Progression
Colella, M., Notaristefano, R., Tragni, M., & Mandorino, M. (2026) · Livers · doi:10.3390/livers6050093 · Cited by 1
Cao, C., Liu, Y., Tan, X., Zhao, Y., Jaime, H., Chu, Y., He, M., Hua, R., Yao, Q., & Shao, Y. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02212-1
Stéatohépatite associée à un dysfonctionnement métabolique (MASH) : prise en charge
Farrugia, M. A., Gual, P., & Anty, R. (2026) · EMC - Hépatologie · doi:10.1016/s1155-1976(25)50657-5
Reichert, M., Strowitzki, M. J., Tuffs, C., Amati, A., Amin, D., Raj, S., Sprenger, T., Hecker, A., & Schneider, M. (2026) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2927-4771
Almujaidel, A., & Marzouk, E. (2026) · Nutrients · doi:10.3390/nu18193202
“In patients with obesity, bariatric surgery has been associated with marked histological improvement, including long-term resolution of steatohepatitis and progressive fibrosis regression [32].”
Li, H., Wang, C., Zhang, W., Wu, W., Pan, Z., Ma, H., Gao, R., Chen, Z., Ji, Q., You, H., et al. (2026) · International Journal of Clinical and Experimental Pathology · doi:10.62347/miva5829
Xie, Z., & Chen, T. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1919204
Sun, Y., Liu, Y., Chen, X., 邓世洲, Zhang, N., Wu, F., Fan, D., Wang, Y., & Wang, Y. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00607-0
“The long-term resolution of MASH and regression of fibrosis after bariatric surgery further indicate that its effects extend beyond body-weight reduction [31, 37].”
Remodeling of Oncogene-Related Molecular Networks Following Bariatric Surgery: a Multi-Omics Study
salhi, M., Al-Shahabi, S., Khatoon, S., Asif, A., Naeem, M., Chowdhury, M. E. H., Pedersen, S., Shahid, F., Khan, M. J., Shi, Z., et al. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08959-w
“Proteomic analysis also predicted inhibition of several cancer-related biological functions and GAIT translation while EIF2 signaling and predicted activation of cell-cycle checkpoint pathways suggesting changes in protein synthesis, cellular stress responses, and cell-cycle regulation [28].”
12 167Metabolische Dysfunktion-assoziierte steatotische Lebererkrankung (MASLD)
Rau, M., & Plauth, M. (2026) · De Gruyter eBooks · doi:10.1515/9783112213056-012
Li, S., Yang, Z., Huang, X., 仲明惟, Lin, S., Liu, T., Zhao, H., 刘少壮, Zhao, S., & Chen, Z.-J. (2026) · Hepatology International · doi:10.1007/s12072-026-11159-4
Takano, H., Poudel, S., Wada, H., Nitta, T., Ebihara, Y., Shichinohe, T., & Hirano, S. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08979-6
Insulin resistance and hepatic steatosis
Tomović, A., Bakovic, N., Pantić, I., Baljosevic, N., Ranković, I., & Alempijevic, T. M. (2026) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2026.102150
Syed‐Abdul, M. M. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2749643
Reytor-González, C., Román-Galeano, N. M., Gavilanes, D. J., Rossetti, G., Cobellis, L., Pilone, V., Simancas‐Racines, D., & Schiavo, L. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100348
“The discordant kinetics of steatosis clearance, insulin-sensitivity restoration, mitochondrial adaptation, and fibrosis regression indicate that hepatic recovery comprises several biologically distinct processes rather than a single weight-dependent pathway [13, 49,54].”
Corrao, S., & Argano, C. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1920879
Metabolic Dysfunction‐Associated Steatotic Liver Disease
Kanwal, F., & Wong, V. W. S. (2026) · Wiley eBooks · doi:10.1002/9781394360031.ch31
Burguera, B. G. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.09.002
Challenges in obese liver transplant recipients
Surendran, S., Bharathan, V. K., & Varghese, C. T. (2026) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000001321
Metadata
- Authors
- Lassailly, G., Caiazzo, R., Ntandja-Wandji, L.-C., Gnemmi, V., Baud, G., Verkindt, H., Ningarhari, M., Louvet, A., Leteurtre, E., Raverdy, V., Dharancy, S., Pattou, F., & Mathurin, P.
- Affiliations
- Inserm (FR)
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Pattou, François
- Mathurin, Philippe
- ORCID
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2020-10
- Volume
- 159
- Issue
- 4
- Pages
- 1290-1301.e5
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W3034346518
- Cited by
- 622
- References
- 27
- Citations by year
- 2026: 93 · 2025: 105 · 2024: 109 · 2023: 106 · 2022: 108 · 2021: 89 · 2020: 11
- FWCI
- 56.22
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Gastroenterology (acceptedVersion, other-oa)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by-nc)
- HAL (submittedVersion)
- LillOA (Université de Lille (University Of Lille)) (submittedVersion, other-oa)
- Funders
- European Regional Development Fund
- Agence Nationale de la Recherche (ANR-10-LABX-46, ANR-16-RHUS-0006)
- Ministère des Affaires Sociales et de la Santé
- European Commission
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Surgery › Organ Transplantation Techniques and Outcomes
- Keywords
- bariatric surgery, nonalcoholic steatohepatitis, liver fibrosis regression, obesity, long-term outcomes, weight loss, NASH resolution, liver biopsy histology, bridging fibrosis, metabolic surgery, liver cancer risk, liver transplantation risk
- MeSH terms
- Adult, Biopsy, Female, Follow-Up Studies, France, Humans, Liver, Liver Cirrhosis, Male, Middle Aged, Obesity, Morbid, Prospective Studies, Remission Induction, Time Factors, Weight Loss, Treatment Outcome, Bariatric Surgery, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
